Sources

13 Total Sources

FDA Approves Sarclisa Escena for 3 Multiple Myeloma Uses

Center100%

Monthly Prescribing Reference16h ago

FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma Treatment

PharmTech16h ago

The Implications of Isatuximab-irfc's FDA Approval for Multiple Myeloma | Pharmaceutical Technology

Oncology News Central16h ago

FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Indications

Oncodaily14h ago

FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma - OncoDaily

AJMC.com Managed Markets Network16h ago

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma | AJMC

Pharmaceutical Executive16h ago

FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma | PharmExec

Curetoday.com16h ago

FDA Approves Sarclisa Escena as a New Under the Skin Treatment Option for Multiple Myeloma | CURE

GuruFocus.com16h ago

Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Esce

Marketscreener.com16h ago

Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector | MarketScreener

Pharmacy Times16h ago

Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma | Pharmacy Times

pharmanow.live16h ago

Sanofi FDA Approval: Subcutaneous Isatuximab-irfc CirCLIQ OBDS | Pharma Now

linkedin17h ago

Super excited! Sarclisa Escena is approved in the US as first anticancer treatment administered via on-body injector, advancing patient and provider centric innovation. | Nihal Tugcu

Isatuximab subcutaneously with the on-body delivery system is now @US_FDA ✓ for multiple myeloma" — @OncBrothers FDA approved (Jul 10) @sanofi's Sarclisa Escena — the first anticancer treatment via an on-body injector —